Establishment and assessment of a novel in vitro bio-PK/PD system in predicting the in vivo pharmacokinetics and pharmacodynamics of cyclophosphamide

Abstract 1. A novel bio-pharmacokinetic/pharmacodynamic (PK/PD) system was established and assessed in predicting the PK parameters and PD effects of the model drug cyclophosphamide (CP) considering the interrelationships between drug metabolism, pharmacological effects and dynamic blood circulation processes in vitro. 2. The system contains a peristaltic pump, a reaction chamber with rat liver microsomes (RLMs) encapsulated in pluronic F127–acrylamide–bisacrylamide (FAB) hydrogels, an effector cell chamber and a recirculating pipeline. The metabolism and pharmacological effects of CP (5, 10 and 20 mM) were measured by HPLC and MTT assay. A mathematical model based on mass balance was used to predict the in vitro clearance of CP. In vivo clearance of CP was estimated by in vitro to in vivo extrapolations (IVIVE) and simulations using Simcyp® software. 3. The predicted in vivo clearance of CP at concentrations of 5, 10 and 20 mM was 11.36, 10.12 and 10.68 mL/min/kg, respectively, within two-fold differences compared with the reported 11.1 mL/min/kg. The survival ratio of effector cells during the metabolism and circulation of CP was significantly enhanced. 4. This system may serve as an alternative approach to predict in vivo metabolism, pharmacological effects and toxicity of drugs, ensuring an efficient drug screening process.

[1]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[2]  M. Vidyavathi,et al.  Role of Human Liver Microsomes in In Vitro Metabolism of Drugs—A Review , 2010, Applied biochemistry and biotechnology.

[3]  Weimin Cai,et al.  Encapsulation of liver microsomes into a thermosensitive hydrogel for characterization of drug metabolism and toxicity. , 2013, Biomaterials.

[4]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[5]  Guanghua Gao,et al.  Physiologically Based Pharmacokinetics of Matrine in the Rat after Oral Administration of Pure Chemical and ACAPHA , 2009, Drug Metabolism and Disposition.

[6]  S. Venkatesh,et al.  Role of the development scientist in compound lead selection and optimization. , 2000, Journal of pharmaceutical sciences.

[7]  Tommy B Andersson,et al.  The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human , 2012, Expert opinion on drug metabolism & toxicology.

[8]  W. Humphreys,et al.  Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs , 2016, Drug Metabolism and Disposition.

[9]  Cécile Legallais,et al.  A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening. , 2011, International journal of pharmaceutics.

[10]  Ling He,et al.  Effects of triptolide on the pharmacokinetics of cyclophosphamide in rats: A possible role of CytochromeP3A4 inhibition , 2014, Chinese Journal of Integrative Medicine.

[11]  Weimin Cai,et al.  Application of a New Dynamic Model to Predict the In Vitro Intrinsic Clearance of Tolbutamide Using Rat Microsomes Encapsulated in a Fab Hydrogel , 2016, Drug Metabolism and Disposition.

[12]  Donald E Ingber,et al.  Microengineered physiological biomimicry: organs-on-chips. , 2012, Lab on a chip.

[13]  P. Annaert,et al.  Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity , 2013, Expert opinion on drug metabolism & toxicology.

[14]  J. Sahi,et al.  Hepatocytes as a tool in drug metabolism, transport and safety evaluations in drug discovery. , 2010, Current drug discovery technologies.

[15]  A. Boddy,et al.  Metabolism and Pharmacokinetics of Oxazaphosphorines , 2000, Clinical pharmacokinetics.

[16]  D. Waxman,et al.  ENANTIOSELECTIVE METABOLISM AND CYTOTOXICITY OF R-IFOSFAMIDE AND S-IFOSFAMIDE BY TUMOR CELL-EXPRESSED CYTOCHROMES P450 , 2005, Drug Metabolism and Disposition.

[17]  D. Huh,et al.  Organs-on-chips at the frontiers of drug discovery , 2015, Nature Reviews Drug Discovery.

[18]  D. Moody,et al.  Variables in human liver microsome preparation: impact on the kinetics of l-alpha-acetylmethadol (LAAM) n-demethylation and dextromethorphan O-demethylation. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[19]  Jong Hwan Sung,et al.  Fabrication and characterization of microfluidic liver-on-a-chip using microsomal enzymes. , 2013, Enzyme and microbial technology.

[20]  Hong Lu,et al.  Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat , 2006, Cancer Chemotherapy and Pharmacology.